other material
confidence high
sentiment positive
materiality 0.80
RLY-2608 shows selective PI3Kα inhibition, no Grade 3 hyperglycemia, partial response in breast cancer
Relay Therapeutics, Inc.
- No Grade 3 hyperglycemia, rash, or diarrhea at target exposures; no dose-limiting toxicities or discontinuations.
- Confirmed partial response (RECIST) in metastatic HR+/HER2- breast cancer patient with 12 prior lines of therapy.
- Target exposure (~80%+ mutant PI3Kα inhibition) achieved at 400mg BID monotherapy and 600/800mg BID combination.
- Nine of 16 breast cancer patients with measurable disease had radiographic tumor reductions; 11 remain on treatment.
- Expansion cohorts expected in H2 2023; new first-in-human trial for second PI3Kα inhibitor RLY-5836 initiated April 2023.